Leuprolide Acetate 22.5mg Injection

Leuprolide Acetate 22.5 mg is used primarily to treat advanced prostate cancer through androgen deprivation therapy. It reduces testosterone to castrate levels, slowing tumour growth. It is also used in premenopausal women with hormone receptor-positive breast cancer and in select cases of endometriosis or central precocious puberty.

Yes. Leuprolide Acetate 22.5 mg is the generic equivalent of Lupron Depot 22.5 mg, manufactured by AbbVie in the USA. In the UK, the corresponding branded product is Prostap 3 DCS by Takeda. Eligard 22.5 mg (subcutaneous formulation) is a commonly prescribed alternative in both the USA and EU.

Once every 12 weeks (three months). It is administered by a healthcare professional as an intramuscular depot injection. The extended-release microsphere formulation ensures sustained testosterone suppression throughout the full dosing interval.

Both are three-month depot formulations of leuprolide acetate. The 11.25 mg dose is indicated for endometriosis, uterine fibroids, and IVF protocols. The 22.5 mg dose is used for prostate cancer androgen deprivation therapy and, in some protocols, hormone receptor-positive breast cancer. The higher dose is not used interchangeably with the lower dose.

Androgen deprivation therapy reduces male hormone (testosterone) levels to slow or stop the growth of prostate cancer cells. Leuprolide 22.5 mg achieves this through chemical means — referred to as medical castration — without the need for surgical intervention. It is used across all stages of hormone-sensitive prostate cancer.

Both contain leuprolide acetate 22.5 mg and are given every three months. The main difference is the delivery system and route: Lupron Depot uses a microsphere suspension given intramuscularly, while Eligard uses the Atrigel polymer system and is given subcutaneously. Clinical outcomes are comparable; choice depends on prescriber preference and patient comfort.

Prostap 3 DCS contains leuprorelin acetate — the international non-proprietary name for leuprolide acetate — and is the UK's primary branded equivalent for the 3-month prostate cancer indication. It is manufactured by Takeda and licensed for advanced prostate cancer treatment in the United Kingdom.

Common side effects include hot flushes, night sweats, fatigue, reduced libido, and erectile dysfunction. With long-term use, bone density loss (osteoporosis), weight gain, and mood changes may occur. Men on long-term ADT are often monitored with DEXA scans and may be prescribed bone-protective agents such as bisphosphonates.

Both are GnRH agonists with comparable testosterone suppression and clinical outcomes in prostate cancer. Goserelin (Zoladex) is given as a subcutaneous implant — available in 1-month and 3-month formulations. Leuprolide is administered intramuscularly. Choice is based on prescriber preference, local formulary, and patient suitability.

Leuprolide 22.5 mg every 12 weeks is used as the backbone ADT agent alongside oral antiandrogens such as bicalutamide, enzalutamide, or apalutamide in combination hormonal blockade regimens. The combination is standard practice in high-risk localised and metastatic hormone-sensitive prostate cancer.